
Ionis shares update on CHAMPION Phase 3 clinical trial
Ionis has shared an important update with the Angelman syndrome community about the design of CHAMPION, its Phase 3 clinical trial evaluating ION582 (obudanersen). The
By uniting researchers, medical professionals, and advocates, we aim to make a lasting impact on the lives of those affected. Through your support, we can accelerate scientific breakthroughs and provide hope to individuals and families facing the challenges of Angelman Syndrome every day.

Ionis has shared an important update with the Angelman syndrome community about the design of CHAMPION, its Phase 3 clinical trial evaluating ION582 (obudanersen). The

“Guided by input from the Angelman community, REVEAL was intentionally designed to evaluate obudanersen across a broad range of people living with Angelman syndrome, reflecting

Oak Hill Bio has shared a community letter to the Angelman syndrome community with an important update on the next steps of the development of

MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the U.S. Food
We found solace and purpose through FAST. Their relentless pursuit of a cure resonated with us, and we started our fundraising journey with them.